Moderna（纳斯达克股票代码：MRNA）与Cortexyme（纳斯达克股票代码：CRTX）头对头调查

Moderna (NASDAQ:MRNA – Get Rating) and Cortexyme (NASDAQ:CRTX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Insider & Institutional Ownership

61.2% of Moderna shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 17.3% of Moderna shares are owned by insiders. Comparatively, 27.9% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Get Moderna alerts:

Risk and Volatility

Moderna has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Valuation and Earnings

This table compares Moderna and Cortexyme's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$18.47 billion	3.59	$12.20 billion	$34.03	4.90
Cortexyme	N/A	N/A	-$89.94 million	($2.97)	-0.73

Moderna has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Moderna and Cortexyme, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	1	8	3	0	2.17
Cortexyme	1	3	2	0	2.17

Moderna currently has a consensus target price of $228.00, indicating a potential upside of 36.60%. Cortexyme has a consensus target price of $13.50, indicating a potential upside of 522.12%. Given Cortexyme's higher possible upside, analysts plainly believe Cortexyme is more favorable than Moderna.

Profitability

This table compares Moderna and Cortexyme's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	64.77%	121.86%	65.53%
Cortexyme	N/A	-70.96%	-63.53%

Summary

Moderna beats Cortexyme on 9 of the 12 factors compared between the two stocks.

About Moderna

(Get Rating)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About Cortexyme

(Get Rating)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.